Learn more →
Back to Expert Scholars
dermatologic-oncology / dermatologic-oncologyMelanoma and Uveal Melanoma

Harriet Kluger

哈丽特·克卢格

MD

🏢Yale School of Medicine / Yale Cancer Center(耶鲁医学院/耶鲁癌症中心)🌐USA

Professor of Medicine (Medical Oncology); Co-Director, Yale SPORE in Skin Cancer内科学教授(肿瘤内科);耶鲁皮肤癌SPORE项目联合主任

60
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Harriet Kluger is a leading melanoma specialist at Yale Cancer Center, recognized for her expertise in uveal melanoma, melanoma brain metastases, and novel therapeutics. She co-directs Yale's NCI-funded SPORE in Skin Cancer and has advanced immunotherapy and targeted therapy for these challenging disease presentations.

Share:

🧪Research Fields 研究领域

Dermatologic Oncology皮肤肿瘤学
Melanoma黑色素瘤
Uveal Melanoma葡萄膜黑色素瘤
Brain Metastases脑转移

🎓Key Contributions 主要贡献

Uveal Melanoma Therapeutics

Led clinical trials of novel agents including tebentafusp in uveal melanoma, demonstrating first survival benefit in this rare and chemotherapy-refractory disease.

Melanoma Brain Metastases

Conducted clinical research on checkpoint inhibitors and targeted therapies for melanoma brain metastases, an area historically excluded from major trials, improving outcomes for this poor-prognosis population.

Predictive Biomarkers

Investigated tissue and blood-based biomarkers of immunotherapy response and resistance in melanoma, including tumor mutational burden and immune cell infiltration patterns.

Representative Works 代表性著作

[1]

Tebentafusp in Metastatic Uveal Melanoma (IMCgp100-202)

New England Journal of Medicine (2021)

Landmark trial demonstrating first-ever overall survival benefit in metastatic uveal melanoma with tebentafusp, establishing a new treatment standard for this rare cancer.

[2]

Ipilimumab plus Nivolumab in Melanoma Brain Metastases

Journal of Clinical Oncology (2021)

Demonstrated efficacy of dual checkpoint blockade in active melanoma brain metastases, providing evidence supporting systemic immunotherapy in CNS disease.

[3]

Combined BRAF and MEK Inhibition in Melanoma Brain Metastases

Lancet Oncology (2017)

Showed combined dabrafenib/trametinib intracranial activity in BRAF-mutant melanoma brain metastases, supporting targeted therapy use in CNS disease.

🏆Awards & Recognition 奖项与荣誉

🏆NCI SPORE in Skin Cancer Investigator Award
🏆Yale Cancer Center Research Excellence Award
🏆Society for Melanoma Research Active Member Recognition
🏆ASCO Merit Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 哈丽特·克卢格 的研究动态

Follow Harriet Kluger's research updates

留下邮箱,当我们发布与 Harriet Kluger(Yale School of Medicine / Yale Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment